VIVA BIOTECH has completed the sale of a 2.33% equity stake in Viva Shanghai.
I'm PortAI, I can summarize articles.
VIVA BIOTECH announced that the relevant matters regarding the sale of a 2.33% equity stake in Viva Shanghai have been completed, and the preconditions for the equity transfer have been met. After the completion, Raed Capital Holdings 2Ltd will hold a 2.33% equity stake in Viva Shanghai, reducing VIVA BIOTECH's equity interest in Viva Shanghai to 73.46%. Viva Shanghai remains a subsidiary of VIVA BIOTECH, and its financial performance will continue to be consolidated into the group's financial statements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments